Manchester University NHS Foundation Trust (MFT) in the UK has announced that its blood test could benefit thousands of women eligible for preventative breast cancer drugs.
This highly sensitive hormone test can determine the effectiveness of anastrozole, a drug recommended for post-menopausal women at high risk of developing breast cancer.
According to research, published in the Lancet Oncology, up to 25% of these women may not benefit from taking the drug.
